



Faster, more accurate gold analysis


Quarterly Investor Update

Dirk Treasure, Managing Director & CEO

Brett Coventry, CFO

July 2022

Important notice



The material in this presentation has been prepared by Chrysos Corporation Limited (ASX: C79) ("Chrysos" or the "Company") and is general background information about Chrysos' current activities as at the date of this presentation. The information is given in summary form and does not purport to be complete. It is intended to be read by a professional analyst audience in conjunction with the Company's other announcements to ASX. Information in this presentation, including forecast financial information, should not be considered advice or a recommendation to current shareholders, investors or potential investors, in relation to holding, purchasing or selling securities in the Company, and does not take into account the investment objectives, financial situation or needs of any particular shareholder or investor. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of the information contained in this presentation.

Forward-looking statements

This presentation may contain statements that are, or may be deemed to be, forward-looking statements, for example statements that use words such as "may", "will", "would", "could", "expects", "intends", "anticipates", and other similar words that involve risks and uncertainties. You should not place undue reliance on such forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this document, are expected to take place. No person who has made any forward-looking statements in this document has any intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this document, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company.

This presentation also contains references to certain intentions, expectations and plans of the Company. These intentions, expectations and plans may or may not be achieved. They are based on certain assumptions which may not be met or on which views may differ.

This presentation may contain information that has been derived from publicly available sources that have not been independent verified. No representation or warranty, express or implied, is made as to the accuracy, reliability, adequacy or completeness of this information.

Past performance information in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance

To the maximum extent permitted by law, Chrysos, its subsidiaries and their respective officers, employees, agents and consultants, and any other person involved in the preparation of this presentation, disclaim all liability and responsibility, including, without limitation, any liability arising out of fault or negligence, for any direct or indirect loss which may arise from or be suffered through use or reliance on anything contained in, or omitted from, this presentation.

Financial and operating highlights

Q4 FY22 unaudited Total Revenue of \$4.7m, reflecting 236% YoY growth, compared to Q4 FY21

11

Deployed units

- 2 units deployed in Q4, and 3rd unit rolled out in July, bringing deployed units to 11
- 5 new lease agreements signed in Q4, with 38 units now contracted or deployed

651k

Sample volumes

- +84% YoY to 651k
- Deployed unit utilisation rate of 64% up from 59% in Q4 FY21

\$4.7m

Unaudited Q4 Total Revenue

- +236% Year-on-Year (YoY) revenue growth
- MMAP/AAC Revenue of \$4.4m
- Other Revenue of \$0.3m

\$14.2m

Unaudited FY22 Total Revenue

- +216% growth against FY21 (\$4.5m) and a +3.6% increase on Prospectus forecast of \$13.7m
- MMAP/AAC Revenue of \$13.5m in line with Prospectus
- Other Revenue \$0.7m

\$558.5m

Total Contract Value (TCV)

- +430% growth in TCV compared to Q4 FY21 (\$105m)

\$92m


Cash in bank

- As at 30 June 2022, following Initial Public Offering (IPO) which raised \$65m in new funds

June Quarter 2022

Strong and Sustained Quarter-on-Quarter growth

MMAP, AAC & Other Income



- MMAP revenue continues to build in line with deployments, providing strong reliable cashflows
- AAC revenue also continues to increase both in comparison to the previous quarter
- Deployment of 3 new units, 11 units now deployed and in service
 - 2 units rolled out by 30 June
 - 1 unit deployed post-balance date
- Other Income is significantly higher than forecast, largely attributable to the Company supplying customers with sample jars, which are a key consumable for PhotonAssay


Growth reflects the ongoing performance of existing deployed units and the deployment of additional units throughout the FY22 year

FY22 Total Revenue growth of +216% on FY21 to \$14.2m, a 3.6% increase on Prospectus forecast of \$13.7m

Total Contract Value growth

Underpinned by long-term annuity-style recurring revenue

Deployed Unit Utilisation & Samples Processed



\$558.5m of Total Contract Value committed under existing contracts

Scalable Business Model

- TCV was \$558.5m^{2,3} at the close of the period
- Reflects addition of contracted revenue from 5 new lease agreements signed in Q4
- Provides Chrysos with high visibility to contracted recurring revenue
- Leasing model with no upfront capital burden minimises barriers to customer adoption and enables scalability
- Revenue growth driven by further unit deployments and sustained strong utilisation of Chrysos PhotonAssay™ units, as measured by sample volumes processed
- More than 651K samples processed in Q4, reflecting YoY growth of 84%
- Average Q4 utilisation rate is 64%, in line with Prospectus forecast and up from 59% in Q4 FY21


² TCV is calculated using foreign exchange rates of AUD:USD 0.73, AUD:CAD 0.94 and AUD:GBP 0.56. The USD and CAD rates are based on the average of the 3-month forward curve from Bloomberg in March 2022, per the Chrysos Prospectus and GBP rates are based on the average of the 3-month forward curve from Bloomberg in May 2022.

³ TCV represents the future minimum contracted revenue on PhotonAssay leases (both deployed and committed) that are yet to be invoiced at a point in time, which are subject to the Company's contractual performance obligations and where the Directors consider reasonable certainty exists, may include values associated with exercise of option periods.

New lease agreements

Validated by existing customers including three of the four largest laboratories and two of the three largest gold miners by market capitalisation globally

- Five new lease agreements signed during the Quarter
- New contracts include two five-year leases with new customer Britannia Life Sciences, two new leases with existing Chrysos customer, Intertek, and one lease with new customer Alfred Knight Laboratories (AHK)
- PhotonAssay footprint to be expanded in Canada and into Ghana
- 38 contracted and deployed units inclusive of the 11 units currently operating
 - Partnership announced with MSALABS
 - MSALABS is not expected to account for more than 45% of deployed units throughout the deployment schedule



Customers

Intertek SGS ALS

Britannia Life Sciences

Alfred H Knight MSALABS


Barrick Gold Corporation

AGNICO EAGLE / Kirkland Lake Gold

Novo Resources Corp

In summary


Chrysos is well positioned for continued growth



- 1 Q4 FY22 unaudited Total Revenue of \$4.7m, reflecting 236% YoY growth
- 2 38 contracted units including 11 units currently deployed and generating revenue
- 3 Utilisation rate of 64% across deployed units, above minimum contracted utilisation and in line with Prospectus forecast
- 4 Sample volume growth of 84%, with 651K samples processed by deployed PhotonAssay units
- 5 Scalable business model with annuity-style revenue and significant potential upside based on increasing utilisation and decreasing unit costs

Thank you

For more information, please visit chrysos.com.au
or contact us at investors@chrysos.com.au



**CHRYSOS
CORPORATION**
Assays at the speed of light